Literature DB >> 28271398

Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.

Xiao Jun Wang1,2, Alexandre Chan3,4.   

Abstract

Febrile neutropenia (FN) is a common and serious complication among cancer patients undergoing myelosuppressive chemotherapy. FN should be treated as a medical emergency because it can lead to life-threatening complications if appropriate treatment is not initiated immediately. This study provides a critical review on the current management of FN and identifies possible directions to optimize FN management.

Entities:  

Keywords:  Biomarker; Economic evaluation; Febrile neutropenia; Management; Optimization; Patient-reported outcome

Mesh：

Substances：

Year:  2017        PMID： 28271398     DOI： 10.1007/s11912-017-0578-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  63 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

Review 3.  Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

Authors:  Leonard Leibovici; Mical Paul; Michael Cullen; Giampaolo Bucaneve; Anat Gafter-Gvili; Abigail Fraser; Winfried V Kern
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

4.  Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.

Authors:  Dominique Dubois; Ravinder Dhawan; Helgi van de Velde; Dixie Esseltine; Sanjay Gupta; Muriel Viala; Christine de la Loge
Journal:  J Clin Oncol       Date:  2006-01-23       Impact factor: 44.544

5.  Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia.

Authors:  Lennart Persson; Bo Söderquist; Per Engervall; Tomas Vikerfors; Lars-Olof Hansson; Ulf Tidefelt
Journal:  Eur J Haematol       Date:  2005-04       Impact factor: 2.997

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

Review 7.  Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.

Authors:  Marc Esser; Helmut Brunner
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.

Authors:  Jeffrey Crawford; David C Dale; Nicole M Kuderer; Eva Culakova; Marek S Poniewierski; Debra Wolff; Gary H Lyman
Journal:  J Natl Compr Canc Netw       Date:  2008-02       Impact factor: 11.908

Review 9.  Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.

Authors:  Katy L Cooper; Jason Madan; Sophie Whyte; Matt D Stevenson; Ron L Akehurst
Journal:  BMC Cancer       Date:  2011-09-23       Impact factor: 4.430

10.  Time to antibiotics and outcomes in cancer patients with febrile neutropenia.

Authors:  Thomas Perron; Mohamed Emara; Shahid Ahmed
Journal:  BMC Health Serv Res       Date:  2014-04-10       Impact factor: 2.655
View more
  3 in total

Review 1.  Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.

Authors:  Yi Ba; Yuankai Shi; Wenqi Jiang; Jifeng Feng; Ying Cheng; Li Xiao; Qingyuan Zhang; Wensheng Qiu; Binghe Xu; Ruihua Xu; Bo Shen; Zhiguo Luo; Xiaodong Xie; Jianhua Chang; Mengzhao Wang; Yufu Li; Yuerong Shuang; Zuoxing Niu; Bo Liu; Jun Zhang; Li Zhang; Herui Yao; Conghua Xie; Huiqiang Huang; Wangjun Liao; Gongyan Chen; Xiaotian Zhang; Hanxiang An; Yanhong Deng; Ping Gong; Jianping Xiong; Qinghua Yao; Xin An; Cheng Chen; Yanxia Shi; Jialei Wang; Xiaohua Wang; Zhiqiang Wang; Puyuan Xing; Sheng Yang; Chenfei Zhou
Journal:  Cancer Biol Med       Date:  2020-12-15       Impact factor: 4.248

2.  Periodontal inflamed surface area in oral cavity associated with febrile neutropenia in patients with hematologic malignancy undergoing chemotherapy.

Authors:  Hiromi Nishi; Kouji Ohta; Yuri Kuramoto; Hideo Shigeishi; Taiji Obayashi; Yukio Yoshioka; Masaru Konishi; Shuichi Munenaga; Hisao Nagoshi; Tetsumi Yoshida; Noriyasu Fukushima; Naoya Kakimoto; Hiroki Ohge; Hidemi Kurihara; Tatsuo Ichinohe; Hiroyuki Kawaguchi
Journal:  Sci Rep       Date:  2022-02-15       Impact factor: 4.996

3.  The calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.

Authors:  Taras Lysyy; Alshad S Lalani; Elizabeth A Olek; Irmina Diala; John P Geibel
Journal:  Pharmacol Res Perspect       Date:  2019-09-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.